Applied Molecular Transport Inc.
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo

Last updated:

Abstract:

The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Status:
Grant
Type:

Utility

Filling date:

3 Dec 2018

Issue date:

21 Apr 2020